Risk factor
Sufficiently resilient to price shocks
Profitability factor
Very strong margins and returns
About
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is underpriced on P/E, of fair value
Target Price
The average target price of MARKSANS.NS is 221 and suggests 32% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to
Buy
Sell